The XiMo team is committed to research that realizes the capabilities of our current olefin metathesis catalysts, reveals new and exciting technologies, and builds innovative partnerships that unlock novel industry opportunities.
Unusual metathesis catalyst holds stereoselectivity promise
Molybdenum catalyst can make Z-trifluoromethyl-substituted olefins useful for pharmaceuticals, agrochemicals and materials
(Chemistry World Magazine, February 1, 2017, by Melissae Fellet)
Chemistry World Magazine has published an article in the February 2017 issue which describes how Professor Amir Hoveyda (XiMo, Boston College) discovered that a molybdenum metathesis catalyst containing an unconventional ligand can make trifluoromethyl-substituted Z-olefins rapidly and selectively.
05 February 2017
Wax pills for safe and simple olefin metathesis hit the market
Capsules preserve air-sensitive chemicals and forego need for glove boxes
(Chemistry World Magazine, October 19, 2016, by Matthew Gunther)
Chemistry World Magazine has published an article in the October 2016 issue which describes the use and function of XiMo’s CatPac catalyst pills. ‘The catalysts are contained within these paraffin tablets and they can be used very easily.’ (Prof. Amir Hoveyda, XiMo/ Boston College)
8 November 2016
XiMo and Aspira Scientific Launch Air-Stable Metathesis Pills
Delivering Nobel-Winning Catalysis Platform for Rapid Pharmaceutical R&D Screening
SAN FRANCISCO, Calif., October 13, 2015 /PRNewswire/ -- XiMo AG (Lucerne, Switzerland) and Aspira Scientific, Inc. (Milpitas, California) announced today the launch of air-stable catalyst pills (CatPac’s) for metathesis chemistry. The importance of metathesis chemistry was highlighted by the Nobel Prize awarded in 2005 to the pioneers of this application. This industrially-relevant application has been utilized in the production of valuable chemical entities such as pharmaceuticals, specialty chemicals, and polymers.
The CatPac system was developed by XiMo, an emerging metathesis technology company and utilizes proprietary molybdenum (Mo) and tungsten (W) catalysts. “Our catalysts represent exceptional value to the chemical industry, especially in pharmaceutical development, given the low cost of Mo compared to ruthenium (Ru) (100-fold less expensive), and its high body tolerance (non-toxic as opposed to Ru),” said Douglas C. Günthardt, Chairman of XiMo. “We have made these highly active catalysts more convenient to use for rapid screening by formulating them in an air-stable pill format that we call the CatPac,” added Dr. Georg Fráter, COO of XiMo. “Our catalysts are also available in native form on commercial scale.”
“As a provider of innovative chemistry solutions, we are continuously launching novel tools to enable discovery and development,” commented Dr. John Chan, CEO of Aspira Scientific. “We are very excited to deliver a broad Nobel-winning metathesis platform in a user- and IP-friendly manner which has been lacking in industry for some time.” This latest addition complements well Aspira Scientific’s broad portfolio of cutting-edge tools for drug and material development. Detailed product information for Mo-CatPac catalysts are available at: www.aspirasci.com/metathesis.
About Aspira Scientific, Inc.
Aspira Scientific is a science-centric enterprise dedicated to empowering scientists reach their aspirations in chemical R&D. We achieve this goal through reducing the cost of basic and applied research by offering research products with superior value in terms of price and quality. By leveraging a truly global innovation ecosystem, we also make available a broader set of next-generation enabling tools for chemical synthesis. For organizations with developmental programs, we provide custom production services via “Collaborate Locally. Commercialize Globally.™” model to afford exceptional value in terms of innovation, quality and IP assurance, and cost-efficiency. For more information on realizing your scientific aspirations now and tomorrow, please visit www.aspirasci.com.
13 October 2015
Versalis and Elevance Partner in Green Innovation for Premium Applications
Versalis, the chemical subsidiary of Eni, and Elevance Renewable Sciences, Inc., a producer of specialty chemicals from natural oils, have signed a Memorandum of Understanding (MoU) to establish a strategic partnership to develop jointly and scale a new metathesis technology to produce bio-chemicals from vegetable oils.
Versalis and Elevance intend to focus on collaboratively developing and scaling new catalysts, leveraging the significant progress of this technology that has been already accomplished by Elevance. In addition, the partners will assess the design and construction of the first world-scale olefin metathesis-based production that will utilize renewable oils at the Versalis Porto Marghera site; this will also take advantage of existing infrastructures and production streams.
The market applications of the future bio-chemicals production will be personal care, detergents and cleaners, bio-lubricants and oilfield chemicals.
“This partnership with Versalis is a natural next step building on the commercially competitive demonstrations of molybdenum-catalyzed metathesis of natural oils that we have achieved in our partnership with XiMo,” said K’Lynne Johnson, Elevance CEO.
XiMo and Elevance have been working together on molybdenum-catalyzed olefin metathesis reactions involving natural oil esters since 2011, a partnership that has demonstrated the process to be exceptionally efficient, selective and commercially competitive. XiMo's catalysts offer unique reactivity and selectivity levels and profiles; what is more, molybdenum and tungsten salts that constitute the core of XiMo catalysts are approximately 100 times less expensive than those that are required for the competitive catalytic systems. The combination of lower costs and longer term sustainability with high selectivity, increased reliability, and lower catalyst loading render the overall capability and efficiency of XiMo’s technology unparalleled.
"Elevance's partnership with Versalis is a truly exciting opportunity for XiMo to develop new bio-chemicals from natural, renewable materials," said Douglas Günthardt, Chairman of the Board at XiMo AG.
Versalis (Eni) is interfacing with markets through globally oriented strategies and a market-driven product portfolio. It leads the industry in manufacturing intermediates, polyethylene, styrenics and elastomers and is entering the green chemicals and polymers industry partnering with worldwide biotech companies. Versalis prides itself on its wide range of proprietary technologies, wide-reaching distribution network and after-sales assistance.
About Elevance Renewable Sciences
Based in Woodridge, Ill., Elevance Renewable Sciences, Inc. creates valued specialty chemicals from natural oils. Using a Nobel Prize-winning technology called olefin metathesis, the company creates high performance ingredients for use in personal care products, detergents, fuels, lubricants and other specialty chemicals markets.
To learn more about Elevance, visit www.elevance.com.
12 February 2014
XiMo has recently licensed two patents from the Max Planck Institute
Catalysts for the alkyne metathesis
Patent in English | Patent in German
See the corresponding publication:
Practical New Silyoxy-based alkyne metathesis catalysts with optimized activity and selectivity profiles
Molybdenum and Tungsten metal complexes and use thereof as precatalysts for olefin metathesis
Patent in German
See the corresponding publication:
Rendering Schrock-type Molybdenum alkylidene complexes air stable: user friendly precatalysts for alkene Metathesis
3 January 2013
Featuring individuals who have made extraordinary contributions to their fields and to MIT: Professor Richard R. Schrock
Elevance Renewable Sciences,
XiMo AG Announce Significant Advancements in
Technology for Metathesizing Natural Oils
Woodbridge, IL, April 10, 2012